BioInsights - Leveraging a scalable, standardized platform process for suspension-based AAV and LV vector manufacture to accelerate time to clinic

Leveraging a scalable, standardized platform process for suspension-based AAV and LV vector manufacture to accelerate time to clinic

Cell & Gene Therapy Insights 2022; 8(7), 791

DOI: 10.18609/cgti.2022.119

Published: 29 July 2022
FastFacts
Samira Shore

  • Common challenges in the development and commercialization of viral vector products  
  • Advantages of choosing a platform process approach for your viral vector product 
  • Overview of the Patheon™ Quick to Clinic™ viral vector program components 
  • Summary of key performance metrics for Quick to Clinic™ including process yield, impurity profile, etc.  

Samira Shore's career in the CDMO industry spans over then years, with expertise focused on development and manufacturing of monoclonal antibodies, small molecules, and viral vectors. She has technical knowledge of various production methods, analytics, process characterizations, and drugs substance and drug product cGMP manufacturing, as well as experience in general regulatory requirements for gene therapies. Samira received her BS in Biological Science and MS in Biochemistry and Biotechnology.